Cannabis Law Report

FEBRUARY 28, 2022

In the past two decades, pioneering research has rekindled interest in the therapeutic use of psychedelic substances such as psilocybin, ibogaine, and dimethyltryptamine (DMT). Indigenous communities have used them for centuries, and researchers studied them in the 1950s and ‘60s. Glenn Cohen & Mason Marks. 20 February 2022.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

JULY 6, 2021

Congressional report offers overview of CBD/hemp market, policy challenges. The Congressional Research Service (CRS) released a report which says there are “three leading markets for hemp, each based on the part of the plant used: fiber, seed/grain, and flower.” The report notes the USDA must work with the DEA to provide direction.

Hemp 105

Hemp CBD DEA Legalization 105

Veriheal

DECEMBER 27, 2022

Let’s dive into what the research says about these promising new findings and how they might advance the field of psychedelic research. Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. The subjective nature of self-reported data can plague research.

Research and Development 95

Research and Development Therapy Consumption DEA 95

SMPL

AUGUST 14, 2019

The American Bar Association (ABA) adopted a resolution on Monday that calls on Congress to allow states to set their own marijuana policies and recommends rescheduling or descheduling cannabis under federal law. The final part of the resolution discusses the need to support research into cannabis.

Policy 40

Policy Research and Development Marijuana DEA 40

FloridaMarijuana.net

JULY 8, 2018

The National Academies of Sciences reports that PTSD is a stressor-related disorder which develops as a result of a patient’s exposure to a traumatic event. The psychological symptoms that develop because of the trauma affect mood, cognition, memories (both suppression and the inability to form new memories) and physical health.

Strains 190

Strains Indica Hybrid Research and Development 190

Cannabis Law Report

JULY 23, 2021

Drug Enforcement Agency (DEA) to the Alcohol and Tobacco Tax and Trade Bureau (TTB), the Bureau of Alcohol Tobacco Firearms and Explosives (ATF). The bill includes several provisions for additional research to investigate the impact of legalization on public health, driving safety, and similar areas. Research, Training and Prevention.

Research and Development 105

Research and Development DEA Programs State Laws 105

Cannabis Law Report

AUGUST 12, 2022

Drug policy topics have become a consistent feature of the Austin-based event in recent years as more states have legalized cannabis and moved to reform laws around psychedelics like psilocybin locally and at the state level. The panel would center on the evolution of cannabis policy in the U.S.,

Research and Development 52

Research and Development Events Topical Policy 52

Freedom Leaf

DECEMBER 4, 2018

For the first but not the last time, events on the global stage had an impact on his life, career and research. In 1917, Adams took a position with the National Research Council in Washington, DC and its associated Chemical Warfare Service. Roger Adams’ Cannabis Research Commences. Cannabis was administered to U.S.

CBD 112

CBD Research and Development THC Cannabinoids 112

Veriheal

AUGUST 24, 2022

This campaign was backed by New Approach PAC, a nationwide political organization that is focused on supporting progressive reform surrounding cannabis and criminal justice policies. Research and Testimonials Point to Psychedelics’ Therapeutic Benefits. The Natural Medicine Health Act: Pros and Cons.

Legalization 108

Legalization Medicine Decriminalization Research and Development 108

Cannabis Law Report

JUNE 15, 2021

. – Today, ahead of the 50th anniversary—on June 17—of when President Richard Nixon declared the “war on drugs,” Representatives Bonnie Watson Coleman (D-NJ) and Cori Bush (D-MO) unveiled the Drug Policy Reform Act (DPRA), alongside the Drug Policy Alliance, which has been a strategic partner on the development of the legislation.

Decriminalization 78

Decriminalization Policy Research and Development Data 78

SpeedWeed

MARCH 5, 2021

Having spent more than 25 years studying cannabis policy and scheduling, I take issue with this interpretation. Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Rescheduling cannabis will not necessarily facilitate clinical research. Authors Tracy Gallegos and Neville M.

Business 52

Business Policy Clinical Trials Research and Development 52

Veriheal

SEPTEMBER 9, 2021

However, it’s important to note that — according to the Marijuana Policy Project — each applicant would be required to pay a fee of $3 million. In fact, this year looks set to be one of the most successful years for cannabis reform in the United States so far. . Conversely, the fee is reduced to $1.5 cannabis reform.

Legalization 109

Legalization Recreational Business Retail 109

Cannabis Law Report

SEPTEMBER 20, 2019

DEA increases the cannabis research quota. The Drug Enforcement Administration (DEA) announced annual quotas for the manufacture of controlled substances for research purposes, providing for 7,000 pounds of cannabis to be used in scientific studies. This represents a 30 percent increase from the 2019 cannabis quota.

Vaping 40

Vaping Banking Research and Development DEA 40

Canna Law Blog

MAY 24, 2024

The Drug Enforcement Administration (DEA) published its Notice of Proposed Rulemaking (“NOPR”) last week to much fanfare. In my very quick analysis after the rule dropped, I flagged DEA’s statement that it may develop “marijuana-specific controls” in conjunction with rescheduling. Marijuana-specific controls in schedule III?

DEA 90

DEA Marijuana Research and Development Policy 90

Canna Law Blog

MAY 7, 2020

At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. These cannabis products are used by researchers in the U.S.

DEA 71

DEA Research and Development Cultivation Supply Chain 71

Cannabis Law Report

JULY 1, 2021

On June 30th, the Petrie-Flom Center announced the launch of a three-year research initiative , the Project on Psychedelics Law and Regulation (POPLAR) , which is supported by a generous grant from the Saisei Foundation. POPLAR will publish original law and policy research.

Law 105

Law Research and Development Therapy DEA 105

Canna Law Blog

NOVEMBER 6, 2021

Once off-limits because of federal prohibition, a trickle of research from the 1990s has grown into a stream. But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Research was permitted in the mid-20th century, until the law stepped in.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

MAY 1, 2019

8 In January of this year, Attorney General Jeff Sessions rescinded an Obama-era policy which had de-prioritized federal prosecution of those involved in the cannabis industry in states which had legalized medical or recreational cannabis. any other Federal criminal statute.” 31 See Lisa N. 32 See , e.g., Retail Marijuana Rules, 1 Colo. . §

Legalization 45

Legalization Business Law Cannabis 45

Cannabis Law Report

NOVEMBER 2, 2021

This is a well researched and detailed report and is, we suggest required reading. Research suggests that about one in five people will have an increase in paranoia as a result of the delta-9 THC after consuming cannabis. And that was just the beginning. The Risk of Delta-8 Products with High Delta-9 For Anxiety and Depression.

THC 96

THC CBD Legalization Vaping 96

Cannabis Law Report

SEPTEMBER 1, 2021

3] Further, notwithstanding the determination of the Drug Enforcement Administration (DEA), which is required to defer to the Department of Health and Human Services’ assessment that cannabis has no acceptable medical utility, 37 states and four territories have enacted laws allowing for the medical use of cannabis products. [4] Gordon Gray.

Policy 100

Policy Cannabis Treatment Law 100

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and Cannabinoids: Health, Research and Regulatory Considerations (Position Paper). During the 20 th century, law enforcement and public policy activities have undermined opportunities for scientific exploration. Relevant AAFP Policy. Executive Summary. Marijuana Possession for Personal Use.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Cannabis Law Report

JUNE 1, 2021

Operating expenses : Total SG&A (“SG&A”) expenses in Q4 2021 declined by 25% versus Q4 2020, driven by year-over-year reductions in Sales & Marketing, and Research and Development (“R&D”) expenses. Drug Enforcement Administration (the “DEA”), the U.S. hemp industry in the U.S.,

Data 95

Data Vaping Supply Chain Business 95

Canna Law Blog

MARCH 4, 2020

With respect to ketamine infusion therapy (which is the prime time attraction of ketamine clinics), the medical research based promise is for treatment of chronic neuropathic pain, chronic pain (instead of opioids), and various medication-resistant mental health disorders, including depression, bi-polar disorder, and PTSD (among others).

Therapy 90

Therapy Legalization Chronic Pain DEA 90

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. Rick Doblin founded MAPS as an official 501(c)(3) non-profit research organization on April 8, 1986. Later that year, Doblin sued the DEA for the first time.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Project CBD

AUGUST 23, 2023

A leading California cannabis industry policy influencer, Devitt is currently Director of Regulatory Affairs at CannaCraft & March and Ash. A recent study in the Journal of Cannabis Research revealed that around 85 percent of intoxicating hemp brands lack substantial age verification at checkout. percent on a dry weight basis.”

Cannabinoids 141

Cannabinoids Hemp THC Safety 141

Cannabis Law Report

JUNE 8, 2021

The Minnesota Hemp Association, now rebranded as the Minnesota Cannabis Association is a 501(c)(4) organization providing advocacy, education, business development opportunities to advance the growth and vitality of Minnesota’s cannabis industry from seed to sale. Minnesota Hemp Association updates goals along with its name.

Hemp 102

Hemp Seed-To-Sale Food Research and Development 102

Sensi Seeds

NOVEMBER 28, 2018

But in an email correspondence conducted as research for this article, EFSA denies issuing any statement in relation to CBD in Spain. Irrespective of where the directive came from, policy on CBD has changed. Spanish companies must comply with the change in law, or face fines and/or product confiscation.

CBD 71

CBD Seed-To-Sale Food Research and Development 71

The Cannigma

SEPTEMBER 12, 2021

THC is the most prevalent, famous and researched cannabinoid by far. The first researcher who identified and isolated THC, was the American Roger Adams (Shutterstock). However, the first researcher that identified and isolated THC was the American Roger Adams in the early 1940’s. Who discovered THC? Is THC safe?

THC 98

THC Research and Development Cannabinoids CBD 98

SpeedWeed

JULY 28, 2021

Since Colombia’s medical cannabis market isn’t quite developed yet, most of the medical cannabis ends up in various international markets like the United States, the United Kingdom, Germany and Israel. International Companies Get Involved with Colombia Cannabis Reform. View original article.

Legalization 52

Legalization Seed-To-Sale Pharmaceutical Research and Development 52

The Cannigma

FEBRUARY 16, 2022

Listen & Subscribe: In light of Black History Month, we feel it is important and relevant to talk about how minorities in the United States and around the world have been disproportionately affected by drug policy and the war on drugs. And before we get too deep into trichomes and your research, maybe we’ll circle back.

Trichome 73

Trichome Wellness and Beauty Cannabinoids Cannabis 73

Cannabis Law Report

AUGUST 6, 2021

Operating expenses : Total SG&A (“SG&A”) expenses in Q1 2022 declined by 17% versus Q1 2021, driven by year-over-year reductions in General & Administrative (“G&A”) and Research and Development (“R&D”) expenses partially offset by an increase in Sales & Marketing (“S&M”) expenses. hemp industry in the U.S.,

Vaping 105

Vaping Research and Development Data Business 105

Canna Law Blog

MARCH 7, 2023

Kate Robertson at MJBizDaily reported on March 1, on a first of its kind development in the space. While “not yet fully complaint”, Bright Green already has a memorandum of agreement “approving” its operations to supply bulk cannabis to cannabis researchers from the U.S. Bright Green Corp., EB-5 program.

DEA 70

DEA Research and Development Programs Cannabis 70

Cannabis Law Report

JANUARY 22, 2020

It also directs the Commission to research “important current issues facing law enforcement and the criminal justice system,” and recommends a variety of subjects for study, such as, but not limited to” There is no direct mention of cannabis but a senior DEA appointment we would suggest is a message in itself. WASHINGTON, D.C.

DEA 69

DEA Law Research and Development Strains 69

The Cannigma

MAY 15, 2023

Because ketamine promotes neuroplasticity, or in other words helps “rewire” the brain,” research shows that it can help stop the repetitive negative thoughts and behaviors that are at the core of many mental health conditions. Some programs also provide a comprehensive host of resources on a website or app.

Therapy 78

Therapy Access Blood Pressure Treatment 78

The Blunt Truth

MAY 15, 2020

We’ve got an update on the latest Montana legalization developments. marijuana research. We reported last week on the DOJ’s memo finding that the Drug Enforcement Administration’s cannabis research program is non-compliant with international drug laws. No word yet on any change in policy. montana update.

Banking 106

Banking Research and Development Programs Advocacy 106

Cannabis Law Report

AUGUST 16, 2019

Immediately, regulators in other states with newly legalized programs will seek to avoid similar pitfalls while striking an effective regulatory balance: Oregon’s unlimited license policy is an opposite example of what other states yet prefer to avoid. Florida’s marijuana future is showing promise. In early August , J.

Marijuana 49

Marijuana Research and Development Seed-To-Sale Education 49

Kind Meds (Cannabis Education Blog)

FEBRUARY 7, 2022

As policies become more data-driven and progressive, cultivation and production technologies have continued to improve drastically over the past several years. The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse.

Recreational 52

Recreational Data Cannabis DEA 52